Trial Profile
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2021
Price :
$35
*
At a glance
- Drugs ENERGI F703 (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Sponsors Energesis Pharmaceuticals
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 23 Nov 2020 Status changed from recruiting to completed.
- 02 Sep 2019 Planned End Date changed from 1 Dec 2018 to 28 Mar 2020.